Hyperbaric oxygen therapy, combined with antibiotics and surgical removal of dead tissue, is an effective treatment for gas
gangrene. Clostridia are anaerobic, meaning they thrive in low-oxygen environments. HBOT stops toxin production and inhibits
bacteria from replicating and spreading. Hyperbaric oxygen may also boost the effect of antibiotics, enhance the body’s natural
defenses against bacteria, and help resolve or delay the onset of sepsis, a deadly blood poisoning.
Clostridial Myositis and Myonecrosis (Gas Gangrene)
page in the Undersea and Hyperbaric Medical Society resource library to learn more about gas gangrene, the rationale for
hyperbaric oxygen therapy, and key clinical evidence, outcomes, and success factors.
Clostridium perfringens is not to be confused with antibiotic-resistant Clostridium difficile (C. diff), an increasingly
common source of healthcare-associated infections (HAIs). Gas gangrene does not involve C. diff. Nor can we find any good
clinical evidence on the treatment of C. diff with hyperbaric oxygen. But early treatment of gas gangrene with hyperbaric
oxygen, surgical debridement, and antibiotics combined has been shown to stop toxin production and significantly reduce
mortality and morbidity compared with surgery alone. Do not expect further study. It may be considered unethical to conduct
clinical trials on such gravely ill patients in critical need of standard combination therapy with HBOT.